1 / 18

Cancer Chemotherapy – I

Cancer Chemotherapy – I. Dr. Nasir Ali Afsar MBBS, M.Phil , Ph.D. Senior Lecturer of Pharmacology. WHO Report: Global Leading Causes of Death, 2004. www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html. What is a neoplasm?. Neo + plasm = new growth

triciab
Télécharger la présentation

Cancer Chemotherapy – I

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cancer Chemotherapy – I Dr. Nasir Ali AfsarMBBS, M.Phil, Ph.D. Senior Lecturer of Pharmacology

  2. WHO Report: Global Leading Causes of Death, 2004 www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html

  3. What is a neoplasm? • Neo + plasm = new growth • Loss of responsiveness to normal growth control: • Origin: • Single germ layer • Monoclonic (mostly) • Pleomorphic • Multiple germ layers = teratoma • May be benign or malignant (cancer)

  4. What is a neoplasm? • Signs of Malignancy: • Higher rate of growth • Poor differentiation • Invasion • Local • Distant (metastasis)

  5. Physiology of Cell Proliferation 2nd messenger Growth Factor • REGULATORY GENES • Proto-oncogenes: growth promoting • Anti-oncogenes:Rb, p53 • Apoptosis regulating genes: p53, bcl-2 • DNA repair genes

  6. Genesis of Cancer Altered Gene Expression Overexpression of proto-oncogenes/ Decreased expression of tumor suppressor genes Tumor Development Clonal diversification through additional… Genetic Mutations Inherited/ Acquired Invasion/ Metastasis

  7. Approaches to Cancer Therapy • Remove - Surgery • Kill • ‘Carpet’ bombing, indiscriminate • Radiotherapy • Chemotherapy • Angiogenesis inhibitors • ‘Target’ killing • Immunotherapy • ‘Radical’ recovery • Gene Therapy • Self sufficiency • Response modifiers: ILs, IFN, GFs.

  8. Classification of Chemotherapeutic Agents • Cytotoxic drugs • Alkylating agents and related comp. • Antimetabolites • Natural products • Hormones • Immunoglobulins • Miscellaneous

  9. Alkylating Agents and Related Compounds • Nitrogen mustards • Mechlorethamine • Cyclophosphamide & Ifosfamide • Melphalan • Chlorambucil • Ethylenimines & methylmelamines • Thiotepa • Alkylsulfonates • Busulfan • Nitrosoureas • Carmustine, Lomustine, Semustine • Streptozocin • Triazenes • Dacarbazine, Procarbazine Note: The drugs marked blue are those included in prescribed drug list by the relevant discipline.

  10. Antimetabolites • Purine analogs • 6-Mercaptopurine & Azathioprine • Thioguanine • Fludarabine & Cladribine • Pentostatin • Pyrimidine analogs • 5-FU & Floxuridine • Ara C • Gemcitabine • Folate analogs • Methotrexate (MTX) Note: The drugs marked blue are those included in prescribed drug list by the relevant discipline.

  11. Natural Anticancer Products • Antibiotics • Actinomycin D • Anthracyclins (Doxorubicin, Daunorubicin, Epirubicin, Idarubicin) • Bleomycin • Mitomycin • Enzymes • L-Asparaginase • Antimitotic drugs • Vincaalkaloids • paclitaxel • Topoisomerase-I inhibitors • Campothecinanalogs (Topotecan, Irinotecan) • Topoisomerase-II inhibitors • Epipodophyllotoxins(Etoposide, Teniposide) Note: The drugs marked blue are those included in prescribed drug list by the relevant discipline.

  12. Hormones • GnRH Analogues: Leuprolide (Prostate) • Estrogens: DES, Ethinylesterdiol(Breast, Prostate) • Antiestrogens: Tamoxifen(Breast) • Progestins: Hydroxyprogestrone (Endometrium, Breast) • Androgens: Testosterone (Breast) • Antiandrogens: Flutamide(Prostate) • Adrenocortical Steroids: Prednisone. (Lukemias, Lymphomas, Breast) • Adrenocortical Suppressant: Mitotane, Aminoglutethimide. (Adrenal Cortex) Note: The drugs marked blue are those included in prescribed drug list by the relevant discipline.

  13. Antibodies and TKIs Imatinib(CML) Trastuzumab(Breast) Cetuximab(Colorectal) Bevacizumab(Colorectal, Lung) Note: The drugs marked blue are those included in prescribed drug list by the relevant discipline.

  14. Miscellaneous Chemotherapeutic Agents • Cisplatin, Carboplatin • Hydroxyurea • Procarbazine • Mitotane

  15. The Cell Cycle Specificity of Anticancer Drugs Cell Cycle Non-specific: Acts during all phases, G1, S, G2, M and G0 Example: Alkylating agents Cell Cycle Specific: Acts during active cell cycle; not during G0 Example: Anthracyclines Physiological checkpoints Phase Specific: Acts only during a specific phase Example: as shown

  16. Site of Anticancer Action Immuno-globulins, TKIs, Hormones Vinca alkaloids, Taxanes Anti-metabolites Anti-metabolites http://img.docstoccdn.com/thumb/orig/123224052.png Alkylating Agent and Platinum compounds Blood Vessel Anthracyclines, Bleomycin, Etoposide Asparaginase

  17. Site of Anticancer Action: in Nucleus Lippincott’s Pharmacology, 5e

  18. THANK YOU • Disclaimer: This presentation is only an adjunct to the prescribed Pharmacology textbooks. • REFERENCES • Goodman & Gilman’s Pharmacological Basis of Therapeutics. Ed. 12 • Pharmacology: by Range, Dale & Ritter. Ed. 7 • Katzung’s Basic and Clinical Pharmacology. Ed. 12 • http://emedicine.medscape.com • www.dhs.sa.gov.au

More Related